Form 8-K - Current report:
SEC Accession No. 0001558370-25-002599
Filing Date
2025-03-10
Accepted
2025-03-10 16:46:12
Documents
15
Period of Report
2025-03-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fencf-20250310x8k.htm   iXBRL 8-K 50980
2 EX-99.1 fencf-20250310xex99d1.htm EX-99.1 291697
3 GRAPHIC fencf-20250310xex99d1001.jpg GRAPHIC 2446
  Complete submission text file 0001558370-25-002599.txt   489698

Data Files

Seq Description Document Type Size
4 EX-101.SCH fencf-20250310.xsd EX-101.SCH 3255
5 EX-101.LAB fencf-20250310_lab.xml EX-101.LAB 15926
6 EX-101.PRE fencf-20250310_pre.xml EX-101.PRE 10315
17 EXTRACTED XBRL INSTANCE DOCUMENT fencf-20250310x8k_htm.xml XML 4872
Mailing Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709
Business Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 (919) 636-4530
FENNEC PHARMACEUTICALS INC. (Filer) CIK: 0001211583 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32295 | Film No.: 25724452
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)